In prostate cancer, melanoma, and leukemia, NCX preferentially works in the reverse mode, although the lack of specificity of the KB-R7943 inhibitor used in these investigations complicates the interpretation of the results [35,37]. The gene discussed is TLX2; the disease is Familial prostate cancer.